Implementation of the Quality by Design approach for developing the composition and the manufacturing technology of an injectable drug for intra-articular introduction
Keywords:hyaluronate sodium, chondroitin sodium sulfate, target product quality profile, critical process parameters, control strategy
Aim. To implement the Quality by Design (QbD) approach in order to develop the composition and the manufacturing technology of injectable hyaluronate sodium (HS) in combination with chondroitin sulfate (CS) for intra-articular
Materials and methods. The composition of the solution for injection was developed using samples of the active pharmaceutical ingredient (API) of HS and CS. The approaches of the ICH international guidelines were used to create the QbD protocol. The quality target product profile (QTPP) was developed based on the literature review, analysis of similar drugs and the previous in-house experimental studies. Determination of critical quality assessment (CQA) product indicators was performed by risk analysis for all quality indicators listed in QTPP. The risk assessment of quality indicators was performed by assessing them according to the Risk Priority Number system (hereinafter – RPN) by a 9-point scale. When studying the composition and the manufacturing technology of the injectable solution the quality risk management (QRM) was developed according to the Ishikawa diagram.
Results and discussion. It has been found that the QbD concept is a systematic approach to the drug development. At the first stage QTPP was developed. Based on the QTPP data the CQA indicators were determined, and quality risks were assessed. The critical process parameters (CPP) of the solution for injection based on HS and CS, their control methods, as well as the critical material attributes (CMA) were determined. Based on the data obtained the drug control strategy was proposed taking into account the need to minimize the repetition of control experiments. Using the Isikawa diagram the variability of the material and the process with the environmental factors affecting the quality
of the solution for injection with HS and CS was shown.
Conclusions. Using the basic QbD approaches when developing the composition and the manufacturing technology of an injectable drug for intra-articular introduction it has been found that the route of administration, dose, potency, and consumer properties of the product are important aspects of QTPP. It has been proven that the quality indicators, such as transparency, viscosity, sterility and the quantitative content of API are determined as CQA to achieve the objectives defined in QTPP. The study shows that almost all stages of production are critical, therefore, they need to be constantly monitored and checked to obtain a quality product. In further experimental studies to confirm the composition developed and the manufacturing technology according to QRM it is necessary to focus on such indicators as the solution temperature, stabilization time, degassing mode and filtration conditions.
Fischenko, V. O., Kirichenko, V. I., Yaremin, S. Yu., Branitsky, O. Yu., Karpinskaia, O. D. (2019). Hip osteoarthritis. Clinical and social aspects of disease. Analytical review of the literature. Part I. Travma, 20 (1), 118-125. http://dx.doi.org/10.22141/1608-1706.1.20.2019.158680.
Shuba, V. I. (2016). Ukrainskyi Medychnyi Chasopys, 1 (111), 59–65.
Misula, I. R., Bakaluk, T. G., Salayda, I. N. (2014). Possibilities of traction therapy in patients with knee joint osteoarthrosis. Journal of Health Sciences, 4 (3), 21–26.
Holovach, I. Yu. (2017). Travma, 18 (3), 11–21. https://doi.org/10.22141/1608-1706.3.18.2017.105356.
Nosivets, D. S. (2013). Visnyk Problem biolohii i medytsyny, 1 (104 (4)), 57–63.
Tosun, H. B., Gumustas, S., Agir, I., Uludag, A., Serbest, S., Pepele, D., Ertem, K. (2015). Comparison of the effects of sodium hyaluronate-chondroitin sulphate and corticosteroid in the treatment of lateral epicondylitis: a prospective randomized trial. Journal of Orthopaedic Science, 20 (5), 837–843. doi: 10.1007 / s00776-015-0747-z.
Rivera, F., Bertignone, L., Grandi, G., Camisassa, R., Comaschi, G., Trentini, D. et al. (2016). Effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis: a multicenter prospective study. Journal of Orthopaedics and Traumatology, 17, 27–33. https://doi.org/10.1007/s10195-015-0388-1.
Pharmaceutical Development Q8(R2) : The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. (2009). Available at: https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf.
MOZ Ukrainy. (2011). Nastanova ST-N MOZU 42-3.0:2011 “Likarski zasoby. Farmatsevtychna rozrobka (ICH Q8)”. Kyiv, 33.
MOZ Ukrainy. (2011). Nastanova ST-N MOZU 42-4.2:2011 “Likarski zasoby. Upravlinnia ryzykamy dlia yakosti (ICHQ9)”. Kyiv, 26.
Politis, S. N., Colombo, P., Colombo, G., Rekkas, D. M. (2017). Design of experiments (DoE) in pharmaceutical development. Drug Development and Industrial Pharmacy, 43 (6), 889–901. doi: 10.1080/03639045.2017.1291672.
Saliy, O. O., Los, O. V., Baula, O. P., Matsiutsia, K. F. (2019). Development of the composition and production technology of injection medication for intra-articular introduction based on sodiun hyaluronate. Farmatsevtychnyi Zhurnal, (5), 75–85. doi: 10.32352/0367-3057.5.19.08.
Salii, O. O., Matsiutsia, K. F., Kuryshko, H. H. (2019). Proceeding from Suchasna farmatsiia: istoriia, realii ta perspektyvy rozvytku: materialy nauk.-prakt. konf. z mizhnar. uchastiu, prysviachenoi 20-i richnytsi zasnuvannia Dnia farmatsevtychnoho pratsivnyka Ukrainy (19-20 veres. 2019 r.). (Vols. 1-2. Vol. 1). (pp. 114–116). Kharkiv: NFaU.
Baula, O. P., Ishchenko, O. V., Cherkas, S. S., Bessarabov, V. I., Resnytskyi, I. V. (2019). Visnyk Kyivskoho natsionalnoho universytetu tekhnolohii ta dyzainu. Seriia Tekhnichni nauky, 3 (134), 79–87. doi: 10.30857/1813-6796.2019.3.8.
Beg, S., Sandhu, P. S., Batra, R. S., Khurana, R. K., Singh, B. (2015). QbD-based systematic development of novel optimized solid self-nanoemulsifying drug delivery systems (SNEDDS) of lovastatin with enhanced biopharmaceutical performance. Drug delivery, 22 (6), 765–784. doi: 10.3109/10717544.2014.900154.
Copyright (c) 2021 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).